Wellington Partners

Orcan Energy AG, founded in 2008 and based in Munich, Germany, specializes in the development and sale of energy solutions that convert waste heat into electricity using Organic Rankine Cycle (ORC) technology. The company provides ORC modules designed for various sectors, including industrial, automotive, marine, and biogas markets. Their products, such as the PACK 20.30 and PACK 05.15, effectively transform waste heat from exhaust gases and cooling water into grid-compatible electricity, catering to both high and low temperature applications. Orcan Energy aims to capitalize on the significant energy potential of unused industrial waste heat sources, offering efficient and economical solutions that operate independently and safely, even under partial load conditions. The company has also received support from various German governmental initiatives and maintains a focus on innovative, compact, and cost-effective energy generation technologies. As of October 2020, Orcan Energy AG operates as a subsidiary of E.ON SE.

Carisma Therapeutics is a biotechnology company based in Philadelphia, Pennsylvania, focused on developing innovative cellular immunotherapies for the treatment of solid tumors. Founded in 2016, the company specializes in engineering chimeric antigen receptor (CAR) macrophages and monocytes, which are types of white blood cells that play a crucial role in the immune response. By harnessing advances in macrophage biology and adoptive cell transfer, Carisma aims to enhance cancer therapies, allowing for more effective treatment options for patients with solid tumors. The company is in the clinical stage of development, working to translate its proprietary technology into transformative therapies for various serious diseases.

ImCheck Therapeutics SAS is a biopharmaceutical company based in Marseille, France, founded in 2015. The company specializes in the development of immunotherapeutics aimed at addressing severe unmet medical needs, primarily in the field of immuno-oncology. ImCheck focuses on creating immuno-modulatory antibodies that target members of the butyrophilin super-family of checkpoint molecules, specifically engaging γ9δ2 T cells. Its research and development efforts are directed toward treating various cancers, including breast, gastric, and ovarian cancers, as well as other immune-related diseases. The company's innovative approach positions it at the forefront of next-generation immunotherapy solutions for patients suffering from solid tumors.

Cayaba Care is a maternal health company focused on providing comprehensive support throughout all phases of pregnancy. The company offers community-based clinical services that are enhanced by technology-enabled multidisciplinary care teams. Its platform addresses a range of concerns including mental health, breastfeeding difficulties, spotting, and postpartum follow-up needs. By focusing on alleviating symptoms, pain, and overall stress and anxiety associated with pregnancy, Cayaba Care aims to ensure that women experience a healthy and safe pregnancy journey.

SidekickHealth is a digital therapeutics company focused on preventing and managing chronic diseases. It leverages behavioral economics, gamification, and artificial intelligence to create engaging experiences that facilitate behavior change and enhance health and well-being. The company collaborates with pharmaceutical companies and other organizations to develop personalized lifestyle change programs aimed at improving health outcomes and treatment adherence. Additionally, SidekickHealth connects clinical experts with patient communities and provides data insights to address significant health challenges. Its lifestyle companion app serves as a tool to support individuals on their health journeys.

Provider of digital financial services intended to give SMEs economic freedom in their decisions. The company's services include short-term and long-term loans, capital credits and accounts payable financing through its online platform, enabling clients to easily personalize their financial services as per their needs.

iOmx Therapeutics AG is a Munich-based company specializing in immuno-oncology target discovery and drug development. The company focuses on creating innovative cancer therapeutics that target novel immune checkpoint modulators present on tumor cells. By employing a systematic screening approach of human tumor cells, iOmx has identified several new targets and studied their mechanisms of action. The foundation of its research is based on the principles of cancer immune-checkpoint therapy, which aims to overcome the natural resistance of tumors to immune responses. This resistance is often facilitated by cell surface molecules that activate immune-inhibitory receptors on T cells. By neutralizing these inhibitory interactions, iOmx Therapeutics seeks to reactivate the host immune response, thereby enhancing the effectiveness of cancer treatments.

Quanta is a medical devices company that develops advanced haemodialysis systems for use in the home and clinic. Quanta is focused on the commercialisation and ongoing development of SC+, an innovative cartridge-based haemodialysis system. SC+ is a high performance, compact haemodialysis system providing clinical efficacy by utilising typical flow rates of traditional in-centre machines. SC+ supports the entire ‘Continuum of Care’ for dialysis patients, from nurse-assisted treatment through self-care in centre to home haemodialysis. Their system facilitates the seamless transition between treatment modalities providing the best tool to enable flexibility for patients, and treatment options for physicians.

Automattic is the company behind WordPress.com and WordPress.com VIP, the cloud version of WordPress. Automattic hosts and supports all WordPress.com sites ensuring that there is continuous and strategic development of the software available to its users. Automattic also supports WordPress.com VIP, a premium service designed for large-scale enterprises. WordPress.com VIP combines the benefits of WordPress.com and the ability to run custom code. In addition, WordPress.com VIP offers companies a robust CMS and 24/7 service.

Onward is developing an Implantable Neuro-stimulation System (INS) with real-time motion feedback and uses training tools to rehabilitate patients suffering from neurological disorders such as spinal cord injury (SCI).

UroMems SAS is a French company founded in 2011 and headquartered in Grenoble, specializing in the design, development, and commercialization of implantable medical devices. The company has created the MyoElectroMechanical System, an electronic artificial urinary sphincter (eAUS) aimed at patients suffering from severe urinary incontinence. This device functions by increasing urethral pressure during physically demanding activities and decreasing it when less compression is needed. UroMems emphasizes addressing specific clinical needs that significantly impact patients' quality of life, with a focus on improving surgical treatments and reducing associated side effects.

EGenesis Inc. is a biotechnology company based in Cambridge, Massachusetts, with an additional office in New York. Founded in 2015, the company specializes in gene editing and genome engineering, focusing on the development of human-compatible organs, tissues, and cells for transplantation. EGenesis employs advanced gene editing techniques to create transplantable cells and solid organs, specifically targeting therapeutic applications in kidney and islet cell transplantation. By leveraging its innovative platform, the company aims to transform the field of organ transplantation, providing safe and effective solutions for patients with life-threatening diseases globally.

Carisma Therapeutics is a biotechnology company based in Philadelphia, Pennsylvania, focused on developing innovative cellular immunotherapies for the treatment of solid tumors. Founded in 2016, the company specializes in engineering chimeric antigen receptor (CAR) macrophages and monocytes, which are types of white blood cells that play a crucial role in the immune response. By harnessing advances in macrophage biology and adoptive cell transfer, Carisma aims to enhance cancer therapies, allowing for more effective treatment options for patients with solid tumors. The company is in the clinical stage of development, working to translate its proprietary technology into transformative therapies for various serious diseases.

Koa Health B.V. is a company founded in 2018, headquartered in Amsterdam, with additional offices in Barcelona, the United States, and the United Kingdom. The company specializes in developing digital wellbeing and therapeutic solutions that focus on mental health support for employees. Koa Health's flagship application, koa foundation, provides organizations with tools to enhance their employees' mental well-being. The company integrates the latest clinical research with innovative technologies to offer accessible, personalized, and effective mental health resources. These resources encompass prevention, prediction, and treatment, addressing a wide range of mental health conditions.

Carisma Therapeutics is a biotechnology company based in Philadelphia, Pennsylvania, focused on developing innovative cellular immunotherapies for the treatment of solid tumors. Founded in 2016, the company specializes in engineering chimeric antigen receptor (CAR) macrophages and monocytes, which are types of white blood cells that play a crucial role in the immune response. By harnessing advances in macrophage biology and adoptive cell transfer, Carisma aims to enhance cancer therapies, allowing for more effective treatment options for patients with solid tumors. The company is in the clinical stage of development, working to translate its proprietary technology into transformative therapies for various serious diseases.

IconOVir Bio is a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus therapy to improve the treatment of patients with cancer.

Minervax is pursuing the development of a vaccine against Group B streptococcus (GBS) infections by utilizing a particular fusion protein, which has proved to elicit good protective immunity. A vaccine including this fusion protein will likely elicit protective immunity against many clinically relevant GBS strains.

Adrenomed AG is a clinical-stage biopharmaceutical company based in Hennigsdorf, Germany, specializing in monoclonal antibody therapies aimed at treating sepsis and related conditions. Founded in 2009, the company focuses on developing its lead product candidate, Adrecizumab, a first-in-class humanized monoclonal antibody that targets Adrenomedullin, a peptide hormone crucial for maintaining vascular integrity. Adrecizumab is designed to address life-threatening situations characterized by increased vascular leakage, congestion, and shock, with primary indications including sepsis, septic shock, and acute heart failure. Adrenomed's innovative approach integrates its therapeutic antibody with a specific diagnostic tool that utilizes Adrenomedullin as a biomarker to identify suitable patients for treatment. The company boasts a robust intellectual property portfolio, with patents granted in major markets, securing its business position in the competitive biopharmaceutical landscape.

Koa Health B.V. is a company founded in 2018, headquartered in Amsterdam, with additional offices in Barcelona, the United States, and the United Kingdom. The company specializes in developing digital wellbeing and therapeutic solutions that focus on mental health support for employees. Koa Health's flagship application, koa foundation, provides organizations with tools to enhance their employees' mental well-being. The company integrates the latest clinical research with innovative technologies to offer accessible, personalized, and effective mental health resources. These resources encompass prevention, prediction, and treatment, addressing a wide range of mental health conditions.

SidekickHealth is a digital therapeutics company focused on preventing and managing chronic diseases. It leverages behavioral economics, gamification, and artificial intelligence to create engaging experiences that facilitate behavior change and enhance health and well-being. The company collaborates with pharmaceutical companies and other organizations to develop personalized lifestyle change programs aimed at improving health outcomes and treatment adherence. Additionally, SidekickHealth connects clinical experts with patient communities and provides data insights to address significant health challenges. Its lifestyle companion app serves as a tool to support individuals on their health journeys.

UiPath develops and provides robotic process automation software designed to enhance operational efficiency across various industries. The company offers a comprehensive platform for hyper automation, enabling enterprises to discover, build, manage, and optimize automation opportunities. Key products include UiPath Studio, which allows users to design automation processes with an intuitive graphical interface, and UiPath Orchestrator, which manages automation workflows and deployments. UiPath’s solutions cater to a variety of sectors, including finance, healthcare, insurance, and telecommunications, facilitating the automation of tasks such as accounts payable, claims processing, and customer service. Founded in 2005 and headquartered in New York, UiPath also has offices in several major cities worldwide, including London, Bucharest, and Tokyo. The company focuses on integrating advanced technologies, such as artificial intelligence, to streamline processes and improve business outcomes.

UiPath develops and provides robotic process automation software designed to enhance operational efficiency across various industries. The company offers a comprehensive platform for hyper automation, enabling enterprises to discover, build, manage, and optimize automation opportunities. Key products include UiPath Studio, which allows users to design automation processes with an intuitive graphical interface, and UiPath Orchestrator, which manages automation workflows and deployments. UiPath’s solutions cater to a variety of sectors, including finance, healthcare, insurance, and telecommunications, facilitating the automation of tasks such as accounts payable, claims processing, and customer service. Founded in 2005 and headquartered in New York, UiPath also has offices in several major cities worldwide, including London, Bucharest, and Tokyo. The company focuses on integrating advanced technologies, such as artificial intelligence, to streamline processes and improve business outcomes.

Polares Medical S.A. is a medical device company based in Ecublens, Switzerland, with an additional office in Palo Alto, California. The company specializes in developing innovative solutions for patients suffering from mitral valve regurgitation. Its flagship product features a unique trans-catheter mitral valve system that facilitates the replacement of the posterior leaflet with a prosthetic leaflet. This design enables physicians to perform hemi-replacements of the mitral valve, improving coaptation with the native anterior leaflet and offering a less invasive treatment option for patients.

UroMems SAS is a French company founded in 2011 and headquartered in Grenoble, specializing in the design, development, and commercialization of implantable medical devices. The company has created the MyoElectroMechanical System, an electronic artificial urinary sphincter (eAUS) aimed at patients suffering from severe urinary incontinence. This device functions by increasing urethral pressure during physically demanding activities and decreasing it when less compression is needed. UroMems emphasizes addressing specific clinical needs that significantly impact patients' quality of life, with a focus on improving surgical treatments and reducing associated side effects.

SIRS Therapeutics operates as a therapeutics company.

ImCheck Therapeutics SAS is a biopharmaceutical company based in Marseille, France, founded in 2015. The company specializes in the development of immunotherapeutics aimed at addressing severe unmet medical needs, primarily in the field of immuno-oncology. ImCheck focuses on creating immuno-modulatory antibodies that target members of the butyrophilin super-family of checkpoint molecules, specifically engaging γ9δ2 T cells. Its research and development efforts are directed toward treating various cancers, including breast, gastric, and ovarian cancers, as well as other immune-related diseases. The company's innovative approach positions it at the forefront of next-generation immunotherapy solutions for patients suffering from solid tumors.

EGenesis Inc. is a biotechnology company based in Cambridge, Massachusetts, with an additional office in New York. Founded in 2015, the company specializes in gene editing and genome engineering, focusing on the development of human-compatible organs, tissues, and cells for transplantation. EGenesis employs advanced gene editing techniques to create transplantable cells and solid organs, specifically targeting therapeutic applications in kidney and islet cell transplantation. By leveraging its innovative platform, the company aims to transform the field of organ transplantation, providing safe and effective solutions for patients with life-threatening diseases globally.

Stipe Therapeutics, founded in 2018 and based in Aarhus C, Denmark, specializes in developing peptide therapeutics aimed at eliminating tumors and cancer. The company focuses on harnessing the innate immune system to combat cancer by creating first-in-class drugs that target intracellular protein-protein interactions within the STING pathway, a crucial regulator of innate immunity and tumor development. Stipe Therapeutics has successfully identified and validated compounds that enhance the STING pathway, effectively modulating the tumor microenvironment to promote a strong anti-tumoral response.

Themis Bioscience is a start-up biotechnology company developing vaccines to prevent infectious diseases. The company’s development focus is primarily concentrated on emerging and specialist indications, advancing promising vaccines from preclinical to late-stage clinical development phases. We aim to exploit the increasing licensing and acquisition trend to generate value by developing and partnering our technology programs and vaccine candidates. It is our mission to establish Themis as a first class biotech development boutique and to become a preferred licensing partner for leading biotech and pharmaceutical companies.

Quanta is a medical devices company that develops advanced haemodialysis systems for use in the home and clinic. Quanta is focused on the commercialisation and ongoing development of SC+, an innovative cartridge-based haemodialysis system. SC+ is a high performance, compact haemodialysis system providing clinical efficacy by utilising typical flow rates of traditional in-centre machines. SC+ supports the entire ‘Continuum of Care’ for dialysis patients, from nurse-assisted treatment through self-care in centre to home haemodialysis. Their system facilitates the seamless transition between treatment modalities providing the best tool to enable flexibility for patients, and treatment options for physicians.

AMBOSS is a medical technology company with offices in New York, Berlin and Cologne. Its knowledge platform has fundamentally changed the way medical know-how is acquired and utilized at the point-of-care. Students use the interactive library and high-yield question bank for general study and exam preparation, while doctors rely on AMBOSS to make effective clinical decisions guided by evidence-based recommendations. Founded in 2012 by doctors for doctors, the company’s international team has grown to over 200 physicians, scientists and software engineers, all striving to better serve doctors around the world. Today, more than half a million healthcare professionals in over 180 countries rely on AMBOSS.

Confo Therapeutics is a drug discovery company based in Brussels, Belgium, founded in 2015. The company specializes in developing internal drug discovery programs focused on G-protein coupled receptors (GPCRs) to address unmet medical needs. Utilizing its proprietary CONFO® technology, Confo Therapeutics stabilizes inherently unstable functional conformations of GPCRs, providing a robust starting point for drug discovery. This approach reveals previously inaccessible structural features of these receptors, facilitating the identification of novel agonists that enhance therapeutic interventions.

BlackBuck is an online fleet management platform that connects shippers with fleet operators in India. By leveraging technology, it aims to enhance the logistics landscape, making it more reliable and efficient. The platform provides features such as price discovery, route optimization, in-transit tracking, and assurance of timely deliveries. This comprehensive approach not only improves operational productivity for clients but also positively impacts the broader transportation ecosystem, which is crucial for numerous livelihoods. BlackBuck is positioned to drive significant advancements in the transportation sector.

UiPath develops and provides robotic process automation software designed to enhance operational efficiency across various industries. The company offers a comprehensive platform for hyper automation, enabling enterprises to discover, build, manage, and optimize automation opportunities. Key products include UiPath Studio, which allows users to design automation processes with an intuitive graphical interface, and UiPath Orchestrator, which manages automation workflows and deployments. UiPath’s solutions cater to a variety of sectors, including finance, healthcare, insurance, and telecommunications, facilitating the automation of tasks such as accounts payable, claims processing, and customer service. Founded in 2005 and headquartered in New York, UiPath also has offices in several major cities worldwide, including London, Bucharest, and Tokyo. The company focuses on integrating advanced technologies, such as artificial intelligence, to streamline processes and improve business outcomes.

UiPath develops and provides robotic process automation software designed to enhance operational efficiency across various industries. The company offers a comprehensive platform for hyper automation, enabling enterprises to discover, build, manage, and optimize automation opportunities. Key products include UiPath Studio, which allows users to design automation processes with an intuitive graphical interface, and UiPath Orchestrator, which manages automation workflows and deployments. UiPath’s solutions cater to a variety of sectors, including finance, healthcare, insurance, and telecommunications, facilitating the automation of tasks such as accounts payable, claims processing, and customer service. Founded in 2005 and headquartered in New York, UiPath also has offices in several major cities worldwide, including London, Bucharest, and Tokyo. The company focuses on integrating advanced technologies, such as artificial intelligence, to streamline processes and improve business outcomes.

Snipr Biome ApS, founded in 2017 and based in Copenhagen, Denmark, is a biotechnology company focused on developing innovative treatments for microbial diseases using CRISPR technology. The company aims to revolutionize healthcare by employing a programmable approach to target and eliminate harmful bacteria in vivo. By leveraging the adaptive immune system, Snipr Biome's therapies selectively identify and kill bacteria based on their specific DNA sequences. This targeted strategy provides healthcare professionals with advanced options for microbiome engineering, enhancing the precision and efficacy of treatments for bacterial infections.

Import.io Ltd is a provider of a software-as-a-service (SaaS) platform that transforms unstructured web data into structured, machine-readable formats. Founded in 2012 and headquartered in London, with an additional office in Los Gatos, California, the company offers a range of products, including Import.io Extract for automated web data extraction, Import.io Insights for data monitoring and visualization, and Import.io API for integration with various systems and workflows. Their services also encompass competitor price monitoring, compliance monitoring, product matching, and customer sentiment analysis. Import.io serves over 850 customers by delivering comprehensive web data from millions of sources, helping businesses gain insights and maintain a competitive edge in their respective markets.

Tonsser ApS operates a social platform designed for youth football players to track their performance and connect with the broader football community. Founded in 2013 and based in Copenhagen, Denmark, Tonsser facilitates collaboration and communication among players, teams, and coaches, allowing users to create a digital football identity. The platform enables players to analyze their game statistics, build a comprehensive resume of their achievements, and engage with their peers. Users can compete for recognition through various awards and rankings, such as team of the week and top scorer lists. By providing insights and motivation, Tonsser inspires young footballers to improve their skills and showcases their potential to teammates, coaches, and scouts.

Adrenomed AG is a clinical-stage biopharmaceutical company based in Hennigsdorf, Germany, specializing in monoclonal antibody therapies aimed at treating sepsis and related conditions. Founded in 2009, the company focuses on developing its lead product candidate, Adrecizumab, a first-in-class humanized monoclonal antibody that targets Adrenomedullin, a peptide hormone crucial for maintaining vascular integrity. Adrecizumab is designed to address life-threatening situations characterized by increased vascular leakage, congestion, and shock, with primary indications including sepsis, septic shock, and acute heart failure. Adrenomed's innovative approach integrates its therapeutic antibody with a specific diagnostic tool that utilizes Adrenomedullin as a biomarker to identify suitable patients for treatment. The company boasts a robust intellectual property portfolio, with patents granted in major markets, securing its business position in the competitive biopharmaceutical landscape.

Sphingotec GmbH is a biopharmaceutical company based in Brandenburg, Germany, founded in 2002. The company specializes in the development of biomarkers aimed at diagnosing, predicting, and monitoring acute medical conditions, including acute heart failure, acute kidney injury, and circulatory shock. Sphingotec focuses on creating monoclonal antibody therapies combined with targeted diagnostic tests tailored for critically ill patients. These innovations work to neutralize harmful substances in the bloodstream, normalize organ function, and enhance survival rates. Additionally, Sphingotec offers biomarkers that assess kidney and endothelial function in critical conditions, thereby enabling healthcare professionals to improve patient management and accelerate recovery for those with severe health issues.

Polares Medical S.A. is a medical device company based in Ecublens, Switzerland, with an additional office in Palo Alto, California. The company specializes in developing innovative solutions for patients suffering from mitral valve regurgitation. Its flagship product features a unique trans-catheter mitral valve system that facilitates the replacement of the posterior leaflet with a prosthetic leaflet. This design enables physicians to perform hemi-replacements of the mitral valve, improving coaptation with the native anterior leaflet and offering a less invasive treatment option for patients.

Carisma Therapeutics is a biotechnology company based in Philadelphia, Pennsylvania, focused on developing innovative cellular immunotherapies for the treatment of solid tumors. Founded in 2016, the company specializes in engineering chimeric antigen receptor (CAR) macrophages and monocytes, which are types of white blood cells that play a crucial role in the immune response. By harnessing advances in macrophage biology and adoptive cell transfer, Carisma aims to enhance cancer therapies, allowing for more effective treatment options for patients with solid tumors. The company is in the clinical stage of development, working to translate its proprietary technology into transformative therapies for various serious diseases.

TRiCares is a medical device company, devoted to developing a catheter-based valve replacement system for minimal invasive treatment of tricuspid valve regurgitation.

Themis Bioscience is a start-up biotechnology company developing vaccines to prevent infectious diseases. The company’s development focus is primarily concentrated on emerging and specialist indications, advancing promising vaccines from preclinical to late-stage clinical development phases. We aim to exploit the increasing licensing and acquisition trend to generate value by developing and partnering our technology programs and vaccine candidates. It is our mission to establish Themis as a first class biotech development boutique and to become a preferred licensing partner for leading biotech and pharmaceutical companies.

Heliatek GmbH, based in Dresden, Germany, specializes in the development and production of organic solar films and photovoltaic cells. Its flagship product, HeliaSol, is an organic photovoltaics (OPV) solution that can be applied to various surfaces, making it suitable for building retrofitting, automotive applications, and other innovative projects. Heliatek caters to the building and construction material sector, as well as automotive manufacturers, offering tailored products like HeliaFilm for integration into façade and roofing systems. The company is recognized as a leader in organic photovoltaics, leveraging its ultra-light and flexible technology to provide sustainable energy solutions. Established in 2006, Heliatek has formed strategic partnerships with companies such as AGC Glass Europe and Reckli China, and it employs around 160 people across its facilities in Germany. The research and development of its technologies have received support from the Free State of Saxony, the Federal Republic of Germany, and the European Union.

GLO AB is a company dedicated to developing and commercializing advanced LED display products utilizing nanotechnology, with its origins rooted in over a decade of research at Lund University. Founded in 2005 and headquartered in Lund, Sweden, GLO also operates a facility in Sunnyvale, California, where it conducts research and pilot fabrication. The company specializes in direct-emitting red, green, and blue microLED products, catering to various sectors including displays, illumination, and automotive applications. GLO's innovative technology allows for the creation of efficient and stable RGB emitters from a single material system, addressing limitations of traditional LED technology. This breakthrough enables superior color stability and the potential for high-quality white LEDs without phosphor conversion. With over 175 patents in the US, Europe, and Asia, GLO is focused on strengthening its intellectual property and advancing its position in the LED market, particularly in fast-growing regions such as Asia.

Tonsser ApS operates a social platform designed for youth football players to track their performance and connect with the broader football community. Founded in 2013 and based in Copenhagen, Denmark, Tonsser facilitates collaboration and communication among players, teams, and coaches, allowing users to create a digital football identity. The platform enables players to analyze their game statistics, build a comprehensive resume of their achievements, and engage with their peers. Users can compete for recognition through various awards and rankings, such as team of the week and top scorer lists. By providing insights and motivation, Tonsser inspires young footballers to improve their skills and showcases their potential to teammates, coaches, and scouts.

Dalia Research GmbH, founded in 2013 and based in Berlin, Germany, specializes in developing online software solutions for market and opinion research. The company offers a product called Samplive, which facilitates smart data collection through various applications, mobile websites, and social media platforms. Dalia operates in over 100 countries, utilizing the app economy and advanced data science techniques to distribute millions of micro-surveys worldwide. This approach enables the collection and analysis of real-time data on consumer attitudes, public opinion, and market trends. With a diverse team from 19 different countries, Dalia Research aims to generate insights that enhance the understanding of global audiences.

At Latana, we believe there is a better way to do brand tracking. We believe that brand and marketing leaders no longer have to base campaigns on guesswork, spending trillions and not sure at the end if it was worth it. We are passionate about bringing reliable data to the world of brand, finally providing a platform for brand marketing similar to what Google Analytics has been providing for other marketing channels for years. We unravel one of the least understood areas of marketing so you don't have to. Latana is here to help you grow.

GLO AB is a company dedicated to developing and commercializing advanced LED display products utilizing nanotechnology, with its origins rooted in over a decade of research at Lund University. Founded in 2005 and headquartered in Lund, Sweden, GLO also operates a facility in Sunnyvale, California, where it conducts research and pilot fabrication. The company specializes in direct-emitting red, green, and blue microLED products, catering to various sectors including displays, illumination, and automotive applications. GLO's innovative technology allows for the creation of efficient and stable RGB emitters from a single material system, addressing limitations of traditional LED technology. This breakthrough enables superior color stability and the potential for high-quality white LEDs without phosphor conversion. With over 175 patents in the US, Europe, and Asia, GLO is focused on strengthening its intellectual property and advancing its position in the LED market, particularly in fast-growing regions such as Asia.

Artfinder is an online marketplace that connects art lovers with independent artists globally, supporting their livelihoods in over 100 countries. The platform offers a diverse collection of more than 500,000 artworks, including paintings, photography, printmaking, sculpture, and more. Artfinder is notable for being the first Certified B Corporation in the art industry, emphasizing a commitment to social purpose and environmental responsibility alongside profitability. With over 10,000 artists and galleries represented, Artfinder aims to make authentic and affordable art accessible to a broad audience, enabling customers to enhance their homes and workplaces with unique creations. The platform has garnered a substantial following, boasting over 600,000 subscribers worldwide.

Themis Bioscience is a start-up biotechnology company developing vaccines to prevent infectious diseases. The company’s development focus is primarily concentrated on emerging and specialist indications, advancing promising vaccines from preclinical to late-stage clinical development phases. We aim to exploit the increasing licensing and acquisition trend to generate value by developing and partnering our technology programs and vaccine candidates. It is our mission to establish Themis as a first class biotech development boutique and to become a preferred licensing partner for leading biotech and pharmaceutical companies.

UroMems SAS is a French company founded in 2011 and headquartered in Grenoble, specializing in the design, development, and commercialization of implantable medical devices. The company has created the MyoElectroMechanical System, an electronic artificial urinary sphincter (eAUS) aimed at patients suffering from severe urinary incontinence. This device functions by increasing urethral pressure during physically demanding activities and decreasing it when less compression is needed. UroMems emphasizes addressing specific clinical needs that significantly impact patients' quality of life, with a focus on improving surgical treatments and reducing associated side effects.

Heliatek GmbH, based in Dresden, Germany, specializes in the development and production of organic solar films and photovoltaic cells. Its flagship product, HeliaSol, is an organic photovoltaics (OPV) solution that can be applied to various surfaces, making it suitable for building retrofitting, automotive applications, and other innovative projects. Heliatek caters to the building and construction material sector, as well as automotive manufacturers, offering tailored products like HeliaFilm for integration into façade and roofing systems. The company is recognized as a leader in organic photovoltaics, leveraging its ultra-light and flexible technology to provide sustainable energy solutions. Established in 2006, Heliatek has formed strategic partnerships with companies such as AGC Glass Europe and Reckli China, and it employs around 160 people across its facilities in Germany. The research and development of its technologies have received support from the Free State of Saxony, the Federal Republic of Germany, and the European Union.

iOmx Therapeutics AG is a Munich-based company specializing in immuno-oncology target discovery and drug development. The company focuses on creating innovative cancer therapeutics that target novel immune checkpoint modulators present on tumor cells. By employing a systematic screening approach of human tumor cells, iOmx has identified several new targets and studied their mechanisms of action. The foundation of its research is based on the principles of cancer immune-checkpoint therapy, which aims to overcome the natural resistance of tumors to immune responses. This resistance is often facilitated by cell surface molecules that activate immune-inhibitory receptors on T cells. By neutralizing these inhibitory interactions, iOmx Therapeutics seeks to reactivate the host immune response, thereby enhancing the effectiveness of cancer treatments.

Rigontec GmbH is a biopharmaceutical company specializing in RNA-based immunotherapeutics aimed at treating cancer and viral diseases. Founded in 2014 and based in Planegg, Germany, the company focuses on developing compounds that activate the immune receptor retinoic acid-inducible gene I (RIG-I), specifically through its lead product, ImOl100. This compound acts as a minimal mimic of the naturally occurring 3pRNA motif found in viral RNAs, stimulating the immune response effectively. Rigontec's approach circumvents common challenges faced by traditional cancer therapies, such as vaccines and checkpoint inhibitors, by targeting RIG-I pathways to induce tumor cell death and promote long-term immunity. In 2017, Rigontec became a subsidiary of Merck & Co., Inc., enhancing its capabilities in the field of immuno-oncology.

Jellynote is the go-to-destination for over 1 million aspiring musicians; a loyal community who enjoy sheets, tabs and chords, original video content and the opportunity to connect with one-another in the Jellynote universe. Jellynote has developed all of its proprietary technology in-house, delivering an intuitive AI-powered edtech platform to its fans. Jellynote sells premium subscriptions and generates revenue from ads. Jellynote offers over 400,000 songs that you can be played to learn through original artist video master classes, video tutorials, sheets, tabs, chords and instrument view for a wide range of instruments. The game mode provides instant feedback and social mode connects musicians share their tastes in music. The Jellynote universe demonstrates how music can connect people in a world that is getting more and more divided. Available on Smartphone and desktop.

Festicket is an online platform that enables music fans to discover and book tickets and travel packages for music festivals around the globe. By offering a seamless end-to-end experience, Festicket serves as an efficient marketplace for over 1,000 music festivals across 40 countries. The platform connects users with a network of 2,000 suppliers, facilitating accommodation and travel arrangements tailored for festivalgoers. This service caters to the needs of live music enthusiasts, allowing them to plan and enjoy their festival experiences with ease.

Tonsser ApS operates a social platform designed for youth football players to track their performance and connect with the broader football community. Founded in 2013 and based in Copenhagen, Denmark, Tonsser facilitates collaboration and communication among players, teams, and coaches, allowing users to create a digital football identity. The platform enables players to analyze their game statistics, build a comprehensive resume of their achievements, and engage with their peers. Users can compete for recognition through various awards and rankings, such as team of the week and top scorer lists. By providing insights and motivation, Tonsser inspires young footballers to improve their skills and showcases their potential to teammates, coaches, and scouts.

EndoStim, Inc., a medical device company, develops and commercializes neurostimulation solutions for the treatment of gastro-esophageal reflux disease (GERD). Its solutions cover treatment for GERD through electrical stimulation. The company distributes its products throughout Europe, Asia, and Latin America. EndoStim was founded in 2009 and is based in Dallas, Texas.

Workframe offers a workflow optimization platform specifically designed for the commercial real estate industry. This web-based software application enables large corporate tenants, landlords, brokers, and service providers to enhance their operational efficiency by gaining visibility into their workflows. It automates the assignment of critical tasks, accelerates project delivery, and provides real-time updates, which helps in streamlining communication and collaboration. By eliminating time-consuming follow-ups and presenting actionable data, Workframe empowers users to recognize trends, share ideas, and proactively manage risks across various projects, ultimately driving cost savings and improving overall productivity.

Onward is developing an Implantable Neuro-stimulation System (INS) with real-time motion feedback and uses training tools to rehabilitate patients suffering from neurological disorders such as spinal cord injury (SCI).

Onfido Limited is a provider of identity verification solutions that utilizes artificial intelligence to authenticate users' identities through the analysis of government-issued IDs and facial biometrics. Established in 2010 and headquartered in London, the company has expanded its presence globally with offices in several major cities, including San Francisco and New Delhi. Onfido's technology is designed to streamline the identity verification process across various sectors, including financial services, e-commerce, and transportation, helping clients onboard users while minimizing risk. The platform enables businesses to verify identities securely and efficiently, supporting applications in areas such as KYC, fraud detection, and user onboarding. With a client base of over 1,500 organizations, Onfido is positioned to transform how identity verification is approached, facilitating seamless access to services ranging from banking to travel.

Mapillary AB operates an online street-level imagery platform that leverages collaboration, cameras, and computer vision to automate and scale mapping. Founded in 2013 and based in Malmö, Sweden, the company allows users to collect and share street-level images using various cameras, including smartphones and action cameras. Over 500 million images have been contributed by individuals and organizations worldwide, enhancing map data for applications in urban development and the automotive sector. Mapillary's tools facilitate the collection, visualization, and tagging of images while ensuring automatic privacy blurring. The platform is utilized by clients and partners such as the World Bank, HERE, and the Toyota Research Institute, reflecting its significance in improving understanding of global locations through visual data. In June 2020, Mapillary became a subsidiary of Facebook, Inc.

Import.io Ltd is a provider of a software-as-a-service (SaaS) platform that transforms unstructured web data into structured, machine-readable formats. Founded in 2012 and headquartered in London, with an additional office in Los Gatos, California, the company offers a range of products, including Import.io Extract for automated web data extraction, Import.io Insights for data monitoring and visualization, and Import.io API for integration with various systems and workflows. Their services also encompass competitor price monitoring, compliance monitoring, product matching, and customer sentiment analysis. Import.io serves over 850 customers by delivering comprehensive web data from millions of sources, helping businesses gain insights and maintain a competitive edge in their respective markets.

AMBOSS is a medical technology company with offices in New York, Berlin and Cologne. Its knowledge platform has fundamentally changed the way medical know-how is acquired and utilized at the point-of-care. Students use the interactive library and high-yield question bank for general study and exam preparation, while doctors rely on AMBOSS to make effective clinical decisions guided by evidence-based recommendations. Founded in 2012 by doctors for doctors, the company’s international team has grown to over 200 physicians, scientists and software engineers, all striving to better serve doctors around the world. Today, more than half a million healthcare professionals in over 180 countries rely on AMBOSS.

Zopa Limited operates an online marketplace lending platform in the United Kingdom, facilitating peer-to-peer lending by connecting individual borrowers with lenders, including both individuals and institutions. Founded in 2004 and based in London, Zopa offers a variety of loan products, such as car loans, debt consolidation loans, home improvement loans, and wedding loans. The platform categorizes borrowers based on credit ratings and allows lenders to make offers tailored to these grades. Zopa manages the loan process by handling legal paperwork, conducting identity and credit checks, and ensuring repayment through direct debit agreements. The company generates revenue by charging borrowers a fixed fee and lenders a 1% annual fee. Zopa has received multiple awards for its innovation and customer service and is recognized as one of the founding members of the UK's Peer-to-Peer Finance Association.

NEUWAY Pharma GmbH had been founded in April 2014 as the first spin-off from Life Science Inkubator GmbH. NEUWAY is focusing on the preclinical and clinical development of innovative therapeutics for treatment of orphan brain diseases based on its proprietary CNS drug delivery platform. The company also intends to partner its drug delivery technology for other CNS indications.

4SC discovers and develops targeted, small-molecule drugs for the treatment of cancer and autoimmune diseases in indications with high unmet medical needs. These drugs are intended to provide innovative treatment options that are more tolerable and efficacious, and provide a better quality of life.

Soundtrack Your Brand is a Spotify joint venture and the exclusive provider of Spotify Business and Spotify Enterprise. We connect brands and fans, and our vision is to grow the music market and thereby support artists, so that they can give the world more great music

At Latana, we believe there is a better way to do brand tracking. We believe that brand and marketing leaders no longer have to base campaigns on guesswork, spending trillions and not sure at the end if it was worth it. We are passionate about bringing reliable data to the world of brand, finally providing a platform for brand marketing similar to what Google Analytics has been providing for other marketing channels for years. We unravel one of the least understood areas of marketing so you don't have to. Latana is here to help you grow.

Dalia Research GmbH, founded in 2013 and based in Berlin, Germany, specializes in developing online software solutions for market and opinion research. The company offers a product called Samplive, which facilitates smart data collection through various applications, mobile websites, and social media platforms. Dalia operates in over 100 countries, utilizing the app economy and advanced data science techniques to distribute millions of micro-surveys worldwide. This approach enables the collection and analysis of real-time data on consumer attitudes, public opinion, and market trends. With a diverse team from 19 different countries, Dalia Research aims to generate insights that enhance the understanding of global audiences.

Dalia Research GmbH, founded in 2013 and based in Berlin, Germany, specializes in developing online software solutions for market and opinion research. The company offers a product called Samplive, which facilitates smart data collection through various applications, mobile websites, and social media platforms. Dalia operates in over 100 countries, utilizing the app economy and advanced data science techniques to distribute millions of micro-surveys worldwide. This approach enables the collection and analysis of real-time data on consumer attitudes, public opinion, and market trends. With a diverse team from 19 different countries, Dalia Research aims to generate insights that enhance the understanding of global audiences.

EyeEm Mobile GmbH is a photography community and platform that connects photographers with brands and media outlets. Founded in 2011 and based in Berlin, Germany, with additional teams in San Francisco and New York, EyeEm enables photographers of all skill levels to share their work, learn, and interact. The platform hosts a vast collection of over 90 million images contributed by more than 20 million photographers worldwide. EyeEm's offerings include a user-friendly smartphone application that allows photographers to showcase their images, while brands can access high-quality, curated visuals for various purposes, including advertising and digital media. The company's API further facilitates developers in accessing its extensive library of photos and albums.

Rigontec GmbH is a biopharmaceutical company specializing in RNA-based immunotherapeutics aimed at treating cancer and viral diseases. Founded in 2014 and based in Planegg, Germany, the company focuses on developing compounds that activate the immune receptor retinoic acid-inducible gene I (RIG-I), specifically through its lead product, ImOl100. This compound acts as a minimal mimic of the naturally occurring 3pRNA motif found in viral RNAs, stimulating the immune response effectively. Rigontec's approach circumvents common challenges faced by traditional cancer therapies, such as vaccines and checkpoint inhibitors, by targeting RIG-I pathways to induce tumor cell death and promote long-term immunity. In 2017, Rigontec became a subsidiary of Merck & Co., Inc., enhancing its capabilities in the field of immuno-oncology.

Onfido Limited is a provider of identity verification solutions that utilizes artificial intelligence to authenticate users' identities through the analysis of government-issued IDs and facial biometrics. Established in 2010 and headquartered in London, the company has expanded its presence globally with offices in several major cities, including San Francisco and New Delhi. Onfido's technology is designed to streamline the identity verification process across various sectors, including financial services, e-commerce, and transportation, helping clients onboard users while minimizing risk. The platform enables businesses to verify identities securely and efficiently, supporting applications in areas such as KYC, fraud detection, and user onboarding. With a client base of over 1,500 organizations, Onfido is positioned to transform how identity verification is approached, facilitating seamless access to services ranging from banking to travel.

Mapillary AB operates an online street-level imagery platform that leverages collaboration, cameras, and computer vision to automate and scale mapping. Founded in 2013 and based in Malmö, Sweden, the company allows users to collect and share street-level images using various cameras, including smartphones and action cameras. Over 500 million images have been contributed by individuals and organizations worldwide, enhancing map data for applications in urban development and the automotive sector. Mapillary's tools facilitate the collection, visualization, and tagging of images while ensuring automatic privacy blurring. The platform is utilized by clients and partners such as the World Bank, HERE, and the Toyota Research Institute, reflecting its significance in improving understanding of global locations through visual data. In June 2020, Mapillary became a subsidiary of Facebook, Inc.

Hintsa Performance is a leading provider of human high performance services.They offer coaching services and digital tools to improve the life and performance of individuals, teams and entire organisations. Their mission is to guide individuals, teams and organisations to enjoy better life, and consequently better performance.

YPlan is a mobile application that simplifies the process of discovering and booking events. Founded in London in February 2012, it offers users a curated list of local events, allowing them to select, pay, and attend activities on the same day. The platform collaborates with over 3,500 event partners globally, providing a diverse range of options for users to explore and enjoy their city. YPlan has garnered more than 1.5 million users and received extensive positive feedback, including over 1,000 five-star reviews on the App Store. The application also integrates with Apple's PassBook for seamless mobile ticketing, enhancing the user experience.

Cavendish Kinetics, Inc. designs, manufactures, and markets tunable components for RF circuits for cellular handsets, laptops, netbooks, tablets, and other consumer wireless devices. It offers antenna tuners for various RF applications. The company offers its products directly to customers worldwide. Cavendish Kinetics, Inc. was founded in 1994 and is headquartered in San Jose, California with an additional office in s-Hertogenbosch, the Netherlands. As of October 4, 2019, Cavendish Kinetics, Inc. operates as a subsidiary of Qorvo, Inc.

Quanta is a medical devices company that develops advanced haemodialysis systems for use in the home and clinic. Quanta is focused on the commercialisation and ongoing development of SC+, an innovative cartridge-based haemodialysis system. SC+ is a high performance, compact haemodialysis system providing clinical efficacy by utilising typical flow rates of traditional in-centre machines. SC+ supports the entire ‘Continuum of Care’ for dialysis patients, from nurse-assisted treatment through self-care in centre to home haemodialysis. Their system facilitates the seamless transition between treatment modalities providing the best tool to enable flexibility for patients, and treatment options for physicians.

ImevaX GmbH is a biopharmaceutical company based in Munich, Germany, established in 2014. The company specializes in developing targeted vaccines to address chronic and nosocomial infections, with a particular focus on immune evasion factors employed by various pathogens. Its lead candidate, IMX 101, is designed to combat Helicobacter pylori, a bacterium responsible for stomach ulcers and gastric cancer in humans. ImevaX's research highlights the role of specific bacterial factors that enable H. pylori to evade the host immune response, prompting further investigation into similar mechanisms in other infectious pathogens. The company's efforts aim to enhance treatment options and improve health outcomes for patients suffering from these persistent infections.

Rigontec GmbH is a biopharmaceutical company specializing in RNA-based immunotherapeutics aimed at treating cancer and viral diseases. Founded in 2014 and based in Planegg, Germany, the company focuses on developing compounds that activate the immune receptor retinoic acid-inducible gene I (RIG-I), specifically through its lead product, ImOl100. This compound acts as a minimal mimic of the naturally occurring 3pRNA motif found in viral RNAs, stimulating the immune response effectively. Rigontec's approach circumvents common challenges faced by traditional cancer therapies, such as vaccines and checkpoint inhibitors, by targeting RIG-I pathways to induce tumor cell death and promote long-term immunity. In 2017, Rigontec became a subsidiary of Merck & Co., Inc., enhancing its capabilities in the field of immuno-oncology.

Atopix Therapeutics Limited is a clinical-stage biopharmaceutical company based in Oxford, United Kingdom, focused on drug discovery for anti-inflammatory medicines. Founded in 2012, the company develops innovative oral treatments, specifically CRTH2 antagonists, aimed at addressing asthma, chronic allergic conditions, and various atopic diseases, including atopic dermatitis and allergic rhinitis. The lead candidate from Atopix is undergoing a Phase 2 clinical trial for moderate to severe atopic dermatitis at multiple prominent dermatology centers across Europe. As of December 2016, Atopix operates as a subsidiary of Chiesi Farmaceutici S.p.A.

Heliatek GmbH, based in Dresden, Germany, specializes in the development and production of organic solar films and photovoltaic cells. Its flagship product, HeliaSol, is an organic photovoltaics (OPV) solution that can be applied to various surfaces, making it suitable for building retrofitting, automotive applications, and other innovative projects. Heliatek caters to the building and construction material sector, as well as automotive manufacturers, offering tailored products like HeliaFilm for integration into façade and roofing systems. The company is recognized as a leader in organic photovoltaics, leveraging its ultra-light and flexible technology to provide sustainable energy solutions. Established in 2006, Heliatek has formed strategic partnerships with companies such as AGC Glass Europe and Reckli China, and it employs around 160 people across its facilities in Germany. The research and development of its technologies have received support from the Free State of Saxony, the Federal Republic of Germany, and the European Union.

Ztory is a Swedish startup that gives readers access to an ever growing stockpile of magazines, children’s books and other illustrated publications for a fixed price each month. Our mission is to develop peoples interests by connecting them to the best publications on subjects they love.

Festicket is an online platform that enables music fans to discover and book tickets and travel packages for music festivals around the globe. By offering a seamless end-to-end experience, Festicket serves as an efficient marketplace for over 1,000 music festivals across 40 countries. The platform connects users with a network of 2,000 suppliers, facilitating accommodation and travel arrangements tailored for festivalgoers. This service caters to the needs of live music enthusiasts, allowing them to plan and enjoy their festival experiences with ease.

Import.io Ltd is a provider of a software-as-a-service (SaaS) platform that transforms unstructured web data into structured, machine-readable formats. Founded in 2012 and headquartered in London, with an additional office in Los Gatos, California, the company offers a range of products, including Import.io Extract for automated web data extraction, Import.io Insights for data monitoring and visualization, and Import.io API for integration with various systems and workflows. Their services also encompass competitor price monitoring, compliance monitoring, product matching, and customer sentiment analysis. Import.io serves over 850 customers by delivering comprehensive web data from millions of sources, helping businesses gain insights and maintain a competitive edge in their respective markets.

AYOXXA Biosystems GmbH is a biotechnology company based in Cologne, Germany, with additional offices in Singapore and Boston, Massachusetts. Founded in 2010, AYOXXA specializes in life science tools, particularly through its proprietary technology platform for multiplexed protein analysis. The company has developed an innovative biochip technology that enables the simultaneous measurement of multiple protein markers associated with various health conditions, including cancer, allergies, cardiovascular diseases, and infectious diseases. AYOXXA's platform utilizes an in-situ encoded bead array, facilitating the identification and quantification of proteins and biomolecular analytes. This advanced approach to biomarker analysis positions AYOXXA at the forefront of diagnostic technology, allowing for comprehensive testing in a single assay.

Nosto Solutions Oy specializes in e-commerce personalization solutions for online retailers worldwide. Founded in 2011 and headquartered in Helsinki, Finland, the company offers a platform-independent software-as-a-service (SaaS) solution that enables retailers to provide real-time personalized product recommendations throughout the shopping journey. Nosto's technology is designed to enhance the online shopping experience, making it accessible for businesses of all sizes. Their offerings include automated marketing tools such as onsite product recommendations, personalized emails, and targeted advertisements on platforms like Facebook and Instagram. Nosto has served notable clients, including brands like Angry Birds and Intersport, helping retailers increase conversion rates, customer retention, and overall store revenues. The company also has offices in key global markets, including New York, Los Angeles, Berlin, Stockholm, and London.

Definiens specializes in image analysis and data mining solutions tailored for quantitative digital pathology within the life sciences, diagnostics, and healthcare sectors. The company offers software that delivers comprehensive readouts from whole tissue slides, cell-based assays, and full-body scans, enabling the correlation of this data with information from other sources. By automating analysis workflows, Definiens assists pharmaceutical and biotechnology firms, research institutions, clinical service organizations, and pathologists in generating insights that enhance decision-making in research, diagnostics, and therapy. The company's mission is to advance research, contribute to the development of personalized medicine, and improve patient quality of life. Headquartered in Munich, Germany, Definiens also maintains offices across the United States.

NEUWAY Pharma GmbH had been founded in April 2014 as the first spin-off from Life Science Inkubator GmbH. NEUWAY is focusing on the preclinical and clinical development of innovative therapeutics for treatment of orphan brain diseases based on its proprietary CNS drug delivery platform. The company also intends to partner its drug delivery technology for other CNS indications.

Soundtrack Your Brand is a Spotify joint venture and the exclusive provider of Spotify Business and Spotify Enterprise. We connect brands and fans, and our vision is to grow the music market and thereby support artists, so that they can give the world more great music

Jellynote is the go-to-destination for over 1 million aspiring musicians; a loyal community who enjoy sheets, tabs and chords, original video content and the opportunity to connect with one-another in the Jellynote universe. Jellynote has developed all of its proprietary technology in-house, delivering an intuitive AI-powered edtech platform to its fans. Jellynote sells premium subscriptions and generates revenue from ads. Jellynote offers over 400,000 songs that you can be played to learn through original artist video master classes, video tutorials, sheets, tabs, chords and instrument view for a wide range of instruments. The game mode provides instant feedback and social mode connects musicians share their tastes in music. The Jellynote universe demonstrates how music can connect people in a world that is getting more and more divided. Available on Smartphone and desktop.

Opvizor GmbH, founded in 2012 and based in Vienna, Austria, specializes in cloud-based expert systems designed for virtual IT infrastructures. The company's flagship product, Opvizor, is an agent-less Software-as-a-Service application that provides automated support and predictive issue detection, significantly reducing the likelihood of expensive support problems. By analyzing protocol files, configuration data, and performance metrics, Opvizor identifies potential system integrity and security issues, offering comprehensive reports that assist administrators in maintaining optimal system health. The platform employs a crowdsourced pattern recognition approach, utilizing a growing knowledge base that evolves through customer input to enhance its predictive capabilities. This innovative solution enables organizations to stabilize their IT environments, minimize downtime, and optimize performance efficiently.

Dacuda is a computer vision company that redefines the capabilities of cameras with real-time 2D and 3D algorithms. As the leading pioneer in software 3D camera technology, Dacuda's mission is to bring 3D capturing to every consumer by making 3D content creation as easy as taking a video. Dacuda's software 3D camera helps scale existing 3D use cases to consumers with app-based scanning and enables novel experiences for Augmented and Virtual Reality headsets. Dacuda is headquartered in Zurich, Switzerland, with locations in Palo Alto, California and Shanghai, China.. Awards include: Venture Leaders Asia 2014, Gartner Cool Vendor 2013, Entrepreneur of the Year 2012 by Ernst & Young, HEC Prix Strategis 2012, Swiss Economic Award 2011, HSG Entrepreneur of the Year 2011, Swiss Innovation Prize by IDEE SUISSE, Venture Leaders 2010, Venture Kick, ETH Spin-Off Label, CTI Start-up Label